Immunome, Inc. reported a net loss of $73.1 million for the quarter ended June 30, 2026, widening significantly from the $43.4 million loss recorded in the same period last year. The deterioration in profitability was primarily driven by a surge in research and development expenses to $59.9 million and general and administrative costs to $18.3 million. Despite the financial headwinds, the company achieved a critical regulatory milestone: the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for varegacestat, assigning a Prescription Drug User Fee Act (PDUFA) target action date of April 28, 2027. This development positions Immunome for a potential approval and launch of its lead candidate for adults with desmoid tumors later this year.

The widening loss reflects the capital-intensive nature of advancing late-stage clinical programs. Research and development expenses increased by approximately 48% year-over-year, while general and administrative expenses nearly doubled. Total operating expenses reached $78.1 million in Q2 2026, compared to $50.5 million in Q2 2025. Collaboration revenue, which contributed $4.0 million in the prior year period, was zero in the current quarter, further pressuring the bottom line. The company’s cash position remains robust, with $520.0 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing sufficient runway to fund operations into 2028.

Financial Performance Overview

The earnings per share (EPS) came in at $(0.65), missing analyst consensus estimates of $(0.52) by 25 percent. This miss underscores the challenges Immunome faces in managing its burn rate relative to revenue generation capabilities during this pre-commercial phase. Investors will likely scrutinize the operational drivers behind this expansion in losses to assess the sustainability of the company’s current financial trajectory leading up to the potential varegacestat launch.

Pipeline Progress and Strategic Outlook

Beyond the financials, Immunome provided significant updates on its broader oncology pipeline. Detailed Phase 3 RINGSIDE data for varegacestat were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating an 84% reduction in the risk of disease progression or death versus placebo. The trial also met all key secondary endpoints, including a confirmed objective response rate of 56% compared to 9% with placebo. Immunome plans to submit a Marketing Authorization Application to the European Medicines Agency by the end of 2026.

The company also advanced three additional clinical-stage programs. In June 2026, the first patient was dosed in the Phase 1 trial of IM-1617, a first-in-class solid tumor antibody-drug conjugate incorporating HC74. In July 2026, the first patient was dosed in the Phase 1 trial of IM-3050, an investigational fibroblast activation protein (FAP)-targeted radioligand therapy. Additionally, objective responses were observed in participants with B-cell lymphoma in the ongoing Phase 1 trial of IM-1021, with initial data expected to be presented in 2026.

What the Numbers Show

The divergence between rising operational expenditures and stagnant top-line revenue highlights the typical J-curve financial profile of biotechnology firms approaching commercialization. While the $73.1 million net loss is substantial, it is offset by the de-risking of the primary asset, varegacestat, through FDA acceptance. The strong cash balance of $520.0 million mitigates near-term liquidity concerns, allowing management to focus on execution rather than capital raising. The inclusion of $8.8 million in share-based compensation within operating expenses suggests that a portion of the burn rate is non-cash, which may improve free cash flow dynamics if operational efficiencies are realized post-approval.

Wedbush analyst David Nierengarten has reiterated an Outperform rating for Immunome, maintaining a $31 price target. The rating affirmation signals continued confidence in the company's performance prospects.

The research note highlights the firm's stance on Immunome's market position. Immunome trades on the NASDAQ under the ticker symbol IMNM.